Titan Pharmaceuticals — Investor Presentation (February 2019)
20 slides from Titan Pharmaceuticals's investor presentation, Feb 14, 2019
Slide 1: Titan Corporate Presentation | February 2019
Copyright © Titan Pharmaceuticals 2019 Not for Promotional Use Titan Pharmaceuticals Titan Corporate Presentation | February 2019
Slide 2: Forward-looking statements
This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, or the Securities Act, and Section 21 E of the Securities Exchange Act of 1934 , or the Exchange Act . All statements other than statements of historical facts conta
Slide 3: Company Snapshot
A commercial - stage company marketing Probuphine ® for the maintenance treatment of Opioid Use Disorder (OUD) in the U.S. Company Snapshot 3 Probuphine implant formulation of buprenorphine that was reacquired by Titan in mid 2018 • Approved in U.S. and Canada, under regulatory review in EU • An imp
Slide 4: ProNeura Long-Term Drug Delivery Platform
Plasma Drug Levels Time Therapeutic Window ProNeura Oral Delivery ProNeura Long - Term Drug Delivery Platform 4 Drug is released continuously into patient's body through dissolution EVA POLYMER API* IMPLANT BLENDED & EXTRUDED Subdermal Administration *API = Active pharmaceutical ingredient
Slide 5: ProNeura-Based Products & Product Candidates
ProNeura - Based Products & Product Candidates Robust Pipeline 5 Feasibility Programs • Malaria prophylaxis (in collaboration with Walter Reed Army Institute of Research and Southwest Research Institute) non - clinical research funded by WRAIR • Type 2 diabetes with currently approved peptides • Per
Slide 6: Probuphine (buprenorphine) Implant Indication
PROBUPHINE is an implant that contains the medicine buprenorphine. PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low - to - moderate doses (doses no more than 8 mg per day) of a transmucosal bupr
Slide 7: Probuphine A Novel Solution
Probuphine A Novel Solution 7 *European patent was acquired by Molteni in March 2018 Commercial Status: • North American rights reacquired in mid 2018 • Canadian commercialization by Knight Therapeutics Inc. • Rights to EU and other select territories acquired by Molteni Farmaceuticci - currently un
Slide 8: Addiction To Opioids Challenge & Opportunity
Addiction To Opioids Challenge & Opportunity 8 1. McLellan A et al., JAMA 2000;284(13): 1689 - 1695 2. Yokell M et al., Curr Drug Abuse Rev 2011;4(1):28 - 41 3. Sehgal et al., Pain Physician 2012;15:ES67 - 92 4. Earnshaw V et al., Int J Ment Health Addict 2013;11(1): 110 - 122 5. Indivior Half Year
Slide 9: Market Opportunity Growing Unmet Medical Need
Market Opportunity Growing Unmet Medical Need 9 “In 2017, overdose deaths in the United States jumped 10% to about 72,000, the CDC said last week. The new data show that peo ple are dying from opioids that are more potent and more dangerous than were available in years past. The CDC also found that
Slide 10: U.S. Regulatory Strategy
U.S. Regulatory Strategy Assess Potential For Label Expansion 10 New FDA guidance on MAT for opioid addiction* • Encourages development of longer - acting formulations • Acknowledges the need for new drugs that don’t end addiction, but help with aspects of it, such as cravings, or overdoses, with th
Slide 11: Probuphine Relaunch
Probuphine Relaunch 11
Slide 12: Market Readied for Launch
Q4 2018 90 - Day Transition Plan Complete 12 Market Readied for Launch Promotional Materials Prepared for Launch Differentiated & Executable Market Strategy Manufacturing and Logistics In Place Sales force Primed For Launch
Slide 13: Transition To Commercial-Stage Company
Transition To Commercial - Stage Company 13 Marketing Support & Business Information Field Support Information Services Marketing, PR & Brand Development Payor Strategy & Reimbursement Business Analytics & Forecasting Sales Operations, Regulatory & Compliance
Slide 14: Titan Transformed: Development-Stage To Commercial-Stage
Built a commercial infrastructure to support growth • Established a small (~10 seasoned people) commercial and medical affairs team with expertise in: o Sales o Marketing and supply chain logistics o Medical science liaison and training functions o REMS program management o 3rd party payor and medic
Slide 15: U.S. Relaunch: A Focused Segmentation Strategy
U.S. Relaunch A Focused Segmentation Strategy Across 4 Key Segments 15 Engage the top tier subgroup of 75 - 100 highest Probuphine prescribers • Identify practices with emphasis on long - term patient treatment • Work closely with physician’s office staff to identify the right patients and create an
Slide 16: Overview Of Key Activities
Overview Of Key Activities Customer Feedback Mechanism – Full PR Program 16 • Introduced Titan and Probuphine to select payor customers • Conducted a payor advisory board with large plans, PBMs and select IDNs • Implement lobbying strategy at Federal & State levels Provider Caregivers Payor Advocacy
Slide 17: Building Strategic Partnerships For Effective Sales Deployment
AZ UT IN IL NY N J PA OH OH NC SC KS MI VA GA FL AL MS LA TX WA WI TN MD KY MO OK CO WV AR NM IA NE OR MN ID NV WY MT SD ND ME NH VT DE MA CA Certified Health Care Providers Building Strategic Partnerships For Effective Sales Deployment 17 17 Probuphine REMS Certified HCP Northeast Region Midwest Re
Slide 18: Early Signs Of Success
• Highly Focused Market Segmentation & Strategy • Integrative Selling Initiative Showing Positive Impact • Core Messaging Resonating with the Right Clinicians and Patient Population Early Signs Of Success Probuphine Shipments 18 Double - digit increase in Probuphine shipments following assumption of
Slide 19: In Summary
In Summary 19 ProNeura Unique and compelling long - term drug delivery platform Probuphine Only product on market to provide six - month, continuous, non - fluctuating blood levels of buprenorphine by Week 4 for maintenance treatment of OUD Development Pipeline ProNeura product candidates for OUD (
Slide 20: Copyright © Titan Pharmaceuticals 2019 Not for Promotional Use Titan Pharmaceuticals Titan
Copyright © Titan Pharmaceuticals 2019 Not for Promotional Use Titan Pharmaceuticals Titan Corporate Presentation | February 2019
Titan Pharmaceuticals — Investor Presentation (February 2019) on 6ix